Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410735" target="_blank" >RIV/00216208:11130/20:10410735 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/20:10410735

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WKpc367Ujp" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WKpc367Ujp</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21037/cdt.2020.01.12" target="_blank" >10.21037/cdt.2020.01.12</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background

Popis výsledku v původním jazyce

Background: The genetic background of patients with hypertrophic cardiomyopathy (HCM) treated with alcohol septal ablation (ASA) and its relationship to the outcomes are not known. We aimed to investigate whether the outcome of genotype positive (G+) patients differs from genotype negative (G-) patients treated with ASA. Methods: We included 129 HCM patients (mean age 54 +/- 13 years) treated with ASA in a tertiary cardiovascular center and performed next generation sequencing (NGS) based genomic testing. All patients were followed-up three months after the procedure and yearly thereafter. Results: A total of 30 (23%) HCM patients were G+ patients. At the 3-months follow-up, both groups of patients had similar left ventricular outflow tract PG (16.9 +/- 15.7 mmHg in G+ vs. 16.3 +/- 18.8 mmHg in G-, P=0.73) and symptoms (follow-up NYHA class 1.40 +/- 0.62 vs. 1.37 +/- 0.53, P=0.99, follow-up CCS class 0.23 +/- 0.52 vs. 0.36 +/- 0.65, P=0.36). The independent predictors of all-cause mortality were baseline interventricular septum (IVS) thickness (HR 1.12, 95% CI: 1.00-1.26, P=0.049) and age at the time of ASA (HR 1.11, 95% CI: 1.06-1.17, P&lt;0.01). The adjusted all-cause mortality rate did not differ significantly between G+ and G- patients (P=0.52). The adjusted combined mortality event rate did not differ between both groups (P=0.78). Conclusions: Despite more severe phenotype in G+ HCM patients, ASA is an equally effective treatment for LVOTO in G+ patients as it is for treating LVOTO in G- patients. The long-term outcome after ASA is similar in G+ and G- patients.

Název v anglickém jazyce

Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background

Popis výsledku anglicky

Background: The genetic background of patients with hypertrophic cardiomyopathy (HCM) treated with alcohol septal ablation (ASA) and its relationship to the outcomes are not known. We aimed to investigate whether the outcome of genotype positive (G+) patients differs from genotype negative (G-) patients treated with ASA. Methods: We included 129 HCM patients (mean age 54 +/- 13 years) treated with ASA in a tertiary cardiovascular center and performed next generation sequencing (NGS) based genomic testing. All patients were followed-up three months after the procedure and yearly thereafter. Results: A total of 30 (23%) HCM patients were G+ patients. At the 3-months follow-up, both groups of patients had similar left ventricular outflow tract PG (16.9 +/- 15.7 mmHg in G+ vs. 16.3 +/- 18.8 mmHg in G-, P=0.73) and symptoms (follow-up NYHA class 1.40 +/- 0.62 vs. 1.37 +/- 0.53, P=0.99, follow-up CCS class 0.23 +/- 0.52 vs. 0.36 +/- 0.65, P=0.36). The independent predictors of all-cause mortality were baseline interventricular septum (IVS) thickness (HR 1.12, 95% CI: 1.00-1.26, P=0.049) and age at the time of ASA (HR 1.11, 95% CI: 1.06-1.17, P&lt;0.01). The adjusted all-cause mortality rate did not differ significantly between G+ and G- patients (P=0.52). The adjusted combined mortality event rate did not differ between both groups (P=0.78). Conclusions: Despite more severe phenotype in G+ HCM patients, ASA is an equally effective treatment for LVOTO in G+ patients as it is for treating LVOTO in G- patients. The long-term outcome after ASA is similar in G+ and G- patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/NV15-34904A" target="_blank" >NV15-34904A: Sekvenování nové generace k určení časné diagnózy a individualizované léčby hypertrofické kardiomyopatie</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cardiovascular Diagnosis and Therapy

ISSN

2223-3652

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CN - Čínská lidová republika

Počet stran výsledku

8

Strana od-do

193-200

Kód UT WoS článku

000528262000010

EID výsledku v databázi Scopus

2-s2.0-85085984325